Highlights d ASM activity is upregulated in brain and/or plasma of aged humans and mice d Brain endothelial cell is a main contributor of increased ASM in aging d Increased ASM in aging causes BBB impairment and neuronal dysfunction d It is regulated by caveolae-mediated transcytosis and ERM dephosphorylation SUMMARY Although many reports have revealed dysfunction of endothelial cells in aging, resulting in blood-brain barrier (BBB) breakdown, the underlying mechanism or mechanisms remain to be explored. Here, we find that acid sphingomyelinase (ASM) is a critical factor for regulating brain endothelial barrier integrity. ASM is increased in brain endothelium and/or plasma of aged humans and aged mice, leading to BBB disruption by increasing caveolae-mediated transcytosis. Genetic inhibition and endothelial-specific knockdown of ASM in mice ameliorated BBB breakdown and neurocognitive impairment during aging. Using primary mouse brain endothelial cells, we found that ASM regulated the caveolae-cytoskeleton interaction through protein phosphatase 1-mediated ezrin/radixin/moesin (ERM) dephosphorylation and apoptosis. Moreover, mice with conditional ASM overexpression in brain endothelium accelerated significant BBB impairment and neurodegenerative change. Overall, these results reveal a novel role for ASM in the control of neurovascular function in aging, suggesting that ASM may represent a new therapeutic target for anti-aging.
In Brief
Park et al. demonstrate that ASM activity is increased in brain endothelial cells and/ or plasma in aged mice, leading to BBB leakage by caveolae-mediated transcytosis via ERM dephosphorylation. Moreover, specific ASM overexpression in brain endothelium accelerates BBB and neuronal dysfunction.
INTRODUCTION
Aging is the most significant risk factor for neurodegenerative disorders, including mild cognitive impairment, cerebrovascular disease, Parkinson's disease (PD), and Alzheimer's disease (AD) (Mattson and Magnus, 2006) . Many studies have suggested that the aging process is associated with several structural, chemical, and functional changes in the brain, as well as a host of neurocognitive changes (Farkas and Luiten, 2001; Katsimpardi et al., 2014; Mattson and Magnus, 2006; Oomen et al., 2009) . One of the key pathological changes is a deterioration of the bloodbrain barrier (BBB), resulting in blood-to-brain extravasation of circulating molecules and immune cells (Farkas and Luiten, 2001) . Diverse studies have shown that BBB permeability was increased by dysfunction of pericytes, astrocytes, and endothelial cells in aging Zlokovic, 2008) . Although an excessive opening of the BBB may lead to detrimental consequences, as illustrated in neurological disorders like stroke and multiple sclerosis (Ferná ndez-Ló pez et al., 2012; Rosenberg, 2012; Zhao et al., 2015a) , BBB dysfunction as a cause or consequence of neurodegeneration remains a subject of active debate. Some studies have suggested that the BBB remains intact in multiple preclinical AD models (Bien-Ly et al., 2015) , while other studies have reported that BBB disruption occurs in normal aging (Farrall and Wardlaw, 2009) and is increased in patients with dementia (Montagne et al., 2015) .
Acid sphingomyelinase (ASM), which is encoded by the Smpd1 gene, is a key sphingolipid metabolizing enzyme that affects multiple signaling processes, including cell survival, proliferation, and differentiation, but also is important in senescence and apoptosis (Zeidan and Hannun, 2010) . ASM is activated in endothelial cells of numerous diseases associated with vascular dysfunction, such as cardiovascular disease and atherosclerosis (Kornhuber et al., 2015) . The cross-talk between endothelial cells and other neurovascular cells, including pericytes, astrocytes, microglia, and neurons, is crucial for the maintenance of a functional BBB (Zlokovic, 2008) . Studies have shown that enhanced ASM levels might contribute to the pathology in aged brain (Sacket et al., 2009 ). However, whether increased ASM can lead to BBB damage and/or accelerate age-related neurodegeneration remains elusive. Here, we demonstrate for the first time that ASM derived from endothelial cells plays a central role in aging-induced BBB disruption. Increased ASM caused an elevation of endothelial cell permeability via caveolae internalization, resulting in neurological dysfunction. We also show that this observation is likely because ASM evokes the protein phosphatase 1 (PP1)-mediated dephosphorylation of ERM (ezrin, radixin, and moesin) in endothelial cells. Our results suggest new avenues for the development of anti-aging therapeutics by understanding the processes of ASM-mediated BBB disruption in aging.
RESULTS

Endothelial ASM Is Increased in Aging and Causes Brain Endothelial Cell Death
To examine the role of ASM in aging, we first checked the ASM levels in human plasma obtained from individuals of varying age. Compared to the plasma from young individuals, the ASM activity was significantly higher in plasma from older individuals ( Figure 1A) . Similarly, plasma derived from 20-month-old (old) mice showed increased ASM activity compared with plasma derived from 3-month-old (young) mice ( Figure 1B) . No significant differences in plasma sphingolipid levels were found between the two groups (Figures S1A-S1C, S1E, S1H, and S1K). However, acid ceramidase (AC) activity was increased in the plasma derived from aging humans and mice ( Figures S1D and S1N) .
To investigate the tissue-specific contribution of increased ASM activity, we examined ASM levels in the liver, kidney, spleen, heart, lung, stomach, genitals, muscle, fat, and brain. Although ASM activity was substantially increased in spleen, muscle, and brain of old mice compared with young mice, the degree of ASM increase was greater in the brain than other organs ( Figure 1C ). We also found that the robust elevation of ASM in brains of old mice was related to microvessels. ASM levels in isolated cerebral microvessels from old mouse brain was more than 3.6-fold higher than in microvessel-depleted brain homogenates containing neurons and glia ( Figure 1D ), indicating that microvessels were the main contributor of elevated ASM activity in old mouse brain. Moreover, ASM levels in CD31 + cells derived from microvessels were significantly higher in old mice compared with young mice ( Figure 1E ). In contrast, ASM levels in platelet-derived growth factor receptor-b + (PDGFR-b + ) or a-smooth muscle actin + (a-SMA + ) cells revealed a slight increase in old mice ( Figure 1E ). These results confirmed that the brain endothelial cell is a main contributor of increased ASM in old mice ( Figure 1E ). Sphingolipid levels were unchanged in brain or microvessels, although AC activity was increased in brain and microvessels, similar to the plasma result ( Figure S1 ). These findings confirmed that ASM activity was upregulated in aging plasma and endothelial cells and may influence aging progression and/or brain pathogenesis.
To address the relationship between ASM and brain pathology in aging, we generated Smpd1 +/À mice. Complete knockout of ASM lead to the type A and type B forms of the lysosomal storage disorder Niemann-Pick disease, but Smpd1 +/À mice developed normally (Horinouchi et al., 1995) . Compared with old mice, age-matched Smpd1 +/À mice had significantly lower levels of ASM in plasma, brain, brain microvessels (especially endothelium), and microvessel-depleted brain (Figures 1B, 1D, and 1E) . Similar to the preceding results, sphingolipids were unaltered in Smpd1 +/À old mice (Figures S1E-S1M). AC activity were slightly decreased in Smpd1 +/À old mice, but this did not reach statistical significance (Figures S1N-S1P).
Next, to determine whether ASM derived from brain microvessels affects brain microvascular structure in aging, we analyzed the brain vascular patterning through Lycopersicon esculentum lectin florescent staining. Although lectin is a passive dye that may not stain every vessel, it is usually used as a brain endothelial-specific marker (Andreone et al., 2017; Bell et al., 2010; Ben-Zvi et al., 2014) . We found significant reductions in capillary density in old versus young mice. However, Smpd1 +/À old mice showed higher capillary density and a higher number of branch points compared to old mice, indicating that normalization of ASM increased vessel maintenance ( Figure 1F ).
Previous studies reported that the apoptosis signals in endothelial cells affect capillary density and that ASM was involved in this cell death mechanism (Li et al., 2003) . Supporting this concept, we found many apoptotic vessels and string vessels (Brown, 2010) in brain endothelium of old mice, and this was reduced in Smpd1 +/À old mice (Figures 1G and 1H) . All basement membrane marker expression were reduced in old wild-type (WT) mice compared with those in the young group, and this was similar in Smpd1 +/À old mice ( Figure S2A ). To gain more specific insights, we measured apoptosis-related proteins and expression of several pro-or anti-apoptotic genes, which are the major checkpoints for the apoptosis pathway. Brain vessels from old mice showed severe abnormalities in pro-and antiapoptotic signals, while vessels from Smpd1 +/À old mice exhibited normal levels ( Figures S2B and S2C ). Recombinant ASM-treated primary mouse brain endothelial cells (Ridder et al., 2015) also showed elevation of apoptosis, decrease of proliferation, and increase of cell death-related signals .
To address the relationship between hemodynamics and vascular changes in aged mice, we examined the hematological parameters in young and old WT and Smpd1 +/À mice. All mice had normal hematological parameters ( Figures S3A-S3J ), suggesting that red blood cells (RBCs) do not contribute appreciably to the vascular damages in the brain. Collectively, these results suggested that increased endothelial ASM in old mice causes endothelial cell death and genetic inhibition of ASM prevented disruption of brain endothelium in aged mice.
Genetic Inhibition of ASM Reduces BBB Disruption in Old Mice
To examine whether genetic reduction of ASM in aged mice affected BBB integrity, we assessed the brain water content, an indicator of BBB disruption. Water content was significantly increased in brains of old mice compared to those of young mice, but this was decreased in old Smpd1 +/À mice brains ( Figure 2A ). Old mice also demonstrated gross microvascular (B) ASM activity in plasma derived from 3-, 12-, and 20-month-old WT and Smpd1 +/À mice (n = 8 mice per group). (C) ASM activity in liver, kidney, spleen, heart, lung, stomach, genitals, muscle, fat, and brain from 3-and 20-month-old WT mice (n = 3-8 mice per group). (D) Left: ASM activity in total brain from 3-, 12-, and 20-month-old WT and Smpd1 +/À mice (n = 6-8 mice per group), Middle: representative immunoblotting of CD31, Tuj-1, and GFAP in brain microvessels and microvessel-depleted brains. Right: ASM activity in isolated microvessels and microvessel-depleted brains from 3-and 20-month-old WT and Smpd1 +/À mice (n = 6-8 mice per group). (E) Percentage of ASM in endothelial cells (CD31 + ), pericytes (PDGFR-b + ), or smooth muscle cells (a-SMA + ) derived from brain microvessels of 3-and 20-monthold WT and Smpd1 +/À mice (n = 5 mice per group). 
Figure 2. Genetic Inhibition of ASM Reduces BBB Disruption in Old Mice
(A) Water content in brains of 3-and 20-month-old WT and Smpd1 +/À mice (n = 6 mice per group). (B) Left: immunofluorescence images of extravascular fibrin deposits in cortex of mice brain. Scale bars, 50 mm. Right: quantification of extravascular fibrin deposits (n = 6 mice per group). (C) Left: representative immunoblotting of fibrin and thrombin levels in microvessel-depleted brain tissue. Right: quantification of fibrin and thrombin (n = 6 mice per group). (D) Representative in vivo time-lapse multiphoton imaging and quantification data of tetramethylrhodamine (TMR) dextran (molecular weight [MW] = 40 kDa; red) leakage from cortical vessels in 3-and 20-month-old WT and Smpd1 +/À mice (n = 6 mice per group). Arrows in WT old mice point to leakages from cortical vessels. Scale bar, 50 mm. (E) Concentrations of fluorescently labeled dextrans of various molecular sizes in 3-and 20-month-old WT and Smpd1 +/À mice brain lysates (n = 3-4 mice per group). (F) Representative image of fluorescent 150 kDa dextran in 20-month-old WT and Smpd1 +/À mice after staining with anti-CD31 and anti-active caspase-3. Arrow, apoptotic vessels. Scale bar, 20 mm. (G) Left: immunoblotting and quantification of Cav-1 phosphorylation in total brain of 3-and 20-month-old WT and Smpd1 +/À mice (n = 4 mice per group). Right: immunoblotting and quantification of Cav-1 phosphorylation, Cavin1, and EHD2 in isolated microvessels of 3-and 20-month-old WT and Smpd1 +/À mice (n = 4-6 mice per group). (H) EM analysis and quantification of cortical endothelial cells for vesicles in 3-and 20-month-old WT and Smpd1 +/À mice (n = 6 mice per group and 8 capillary cross-sections per mouse). Arrow, cytoplasmic vesicles; arrowhead, luminal vesicles. Scale bar, 500 nm. (I) EM image and quantification of cortical endothelial cells for HRP transcytosis in 3-and 20-month-old WT and Smpd1 +/À mice (n = 4 mice per group and 8 capillary cross-sections per mouse). Scale bar, 500 nm. (J) EM analysis of tight junctions in endothelial cells from 3-and 20-month-old WT and Smpd1 +/À mice. Scale bar, 100 nm. Black arrows point to endothelial junctions. Red arrows indicate microvesicles filled with HRP in endothelium in 20-month-old WT and Smpd1 +/À mice.
(legend continued on next page) leakage and extravascular accumulation of circulating molecules compared with those in young mice. By contrast, there were substantial decreases in parenchymal accumulation of plasma-derived protein in Smpd1 +/À old mice when compared to old mice ( Figures 2B and 2C ). In vivo time-lapse multiphoton imaging showed similar patterns ( Figure 2D ). To increase the confidence of these findings and determine the molecular size limit of solutes that can penetrate the abnormal BBB, we performed a noninvasive fluorometric BBB permeability assay using a consistent set of tracers (4, 70, 150, and 2,000 kDa dextran). Fluorescent tracers were detected in higher concentrations in brain extracts of old mice, but these were decreased in Smpd1 +/À old mice ( Figure 2E ).
To confirm the mechanism responsible for restoration of BBB integrity in Smpd1 +/À old mice, we assessed pericyte coverage and astrocytic endfoot processes, known as components of the BBB, but we did not detect differences between groups (Figures S3K and S3L) . Although zonula occludens-1 (ZO-1) levels were reduced in old mice, this did not recover in Smpd1 +/À old mice. Expression of occludin, claudin5, vascular endothelial (VE)-cadherin, and b-catenin colocalized with vessels (Griffonia [Bandeiraea] simplicifolia lectin I, BSL) did not differ between the groups (Figures S3M-S3Q ). We observed similar results in brain microvessels from each mouse through western blots (Figure S3R) . Moreover, we examined the change of BBB permeability by damage to tight junctions using small molecular weight tracers such as Na-fluorescein, which primarily crosses the BBB when endothelial cell tight junctions are impaired Miner et al., 2015) . The result showed that Na-fluorescein was detected in higher concentrations in brain extracts of old mice compared to those in the young groups but that this leakage did not recover in Smpd1 +/À old mice ( Figure S3S ). Our results indicated that pericyte coverage, astrocytic endfoot processes, and junctional properties were not related to the BBB restoration we observed in Smpd1 +/À old mice.
Breakdown of cerebral blood vessels after endothelial cell death might increase BBB permeability. In aged mice, vessels permeable for dextran outnumbered the active caspase-3-positive vessels, and most leaky vessels did not show an apoptotic signal, implying that the death of endothelial cells is not the main cause of BBB disruption in aging. Although vessel leakage and apoptotic vessels were decreased in Smpd1 +/À old mice, leaky vessels also were found without apoptotic signals in these mice ( Figure 2F ).
Dysfunction of permeability in endothelial cells could affect impairment of BBB, and this is regulated via the transcellular transport pathway (Mehta and Malik, 2006) . Caveolae are known to regulate the vesicle carriers involved in the transcytosis of blood-borne proteins (Mehta and Malik, 2006; Zhao et al., 2014) . We first examined changes of caveolin-1 (Cav-1), a structural protein of caveolae. The phosphorylation of Cav-1, known as an indicator of endothelial transcytosis levels , was significantly increased in brain and isolated brain vessels derived from old mice, but this was reduced in samples derived from Smpd1 +/À old mice ( Figure 2G ). The expression of Cavin1 and Eps15 homology domain containing 2 (EHD2) was not different between the groups, indicating that ASM evokes endocytosis of caveolae without changes to total caveolae expression. ( Figure 2G ).
The endothelium of WT old mice displayed a dramatic increase of cytoplasmic vesicles upon transmission electron microscopy (TEM) analysis, which indicates an increased rate of transcytosis. However, these vesicles reduced in Smpd1 +/À old mice ( Figure 2H ). We next injected horseradish peroxidase (HRP) into WT and Smpd1 +/À mice with age and examined the distribution of HRP in brain vessels by TEM. We found that old mice vessels showed marked accumulation of HRP reactivity in the cytoplasm and that it had exocytosed at the abluminal plasma membrane, indicating that HRP was subject to transcytosis in old mice. However, the amount of HRP transcytosis was decreased in Smpd1 +/À old mice ( Figure 2I ). Moreover, we observed no overt tight junction ultrastructural defect between the groups. However, we observed HRP accumulation without apparent colocalization with tight junctions in either old WT mice or old Smpd1 +/À mice ( Figure 2J ). This observation supported that HRP permeability across the BBB in old mice vessels occurred through a transcytosis route. To confirm caveolaemediated transcytosis, we performed Cav-1 immunoelectron microscopy (immuno-EM) labeling in brains of WT and Smpd1 +/À mice with age. The results showed that there was a significant increase in the number of Cav-1-positive vesicles in endothelial cells of WT old mice compared to young mice. However, these vesicles were decreased in Smpd1 +/À old mice ( Figure 2K ). Therefore, these data suggested that ASM regulated caveolaemediated transcytosis in the aging brain.
In BBB endothelial cells, multiple transporters exist in the membrane and act as protective pumps for BBB integrity (Begley, 2004) . Our findings regarding phosphorylated Cav-1 prompted investigation of additional caveolae-dependent endothelial cell molecules, such as BBB transporters. We found that some transporter proteins were significantly decreased in brain microvessels derived from old mice and recovered in Smpd1 +/À old mice ( Figures 2L and 2M ). Although mRNA expression of glucose transporter-1 (GLUT1) was decreased in Smpd1 +/À old mice, this did not affect protein levels ( Figures 2L and 2M ). The restoration of transporters in Smpd1 +/À old mice might be related to reduction of caveolae internalization in these mice. Collectively, our findings indicated that genetic inhibition of ASM reduced BBB (K) Cav-1 immuno-EM analysis (left) and quantification (right) of cortical endothelial cells in 3-and 20-month-old WT and Smpd1 +/À mice (n = 4 mice per group and 8 capillary cross-sections per mouse). Arrows, luminal vesicles; , arrowheads, abluminal or cytoplasmic vesicles. Gold particles (black puncta) are visualized along the luminal (arrows) and abluminal (arrowheads) plasma membranes, as well as within the cytoplasm. Scale bar: low magnification, 500 nm; high magnification, 200 nm. (L) mRNA expression levels of BBB transporters were evaluated in the isolated brain microvessels of 3-and 20-month-old WT and Smpd1 +/À mice (n = 4-6 mice per group). (M) Western blot analysis of transporters in the isolated brain microvessels of 3-and 20-month-old WT and Smpd1 +/À mice (n = 4-5 mice per group). (A-E, G-I, and K-M) One-way ANOVA and Tukey's post hoc test. *p < 0.05, **p < 0.01. All error bars indicate SEM. See also Figure S3 . disruption in old mice and that caveolae-mediated transcytosis regulated by ASM might be an important mechanism that attenuates BBB disruption in aging.
Restoration of ASM Delays Neurodegenerative Changes in Old Mice
We quantified the neuron-specific nuclear protein A60-positive (NeuN + ) cells in the brain of mice. NeuN + cells were significantly decreased in the brains of WT old mice, but not in those of Smpd1 +/À old mice ( Figure 3A ). We also checked for gross alterations in brain architecture through measurement of mean cortical diameter, an index of brain size. This analysis demonstrated 8% reductions in old mice but no significant alterations in brain size in Smpd1 +/À old mice ( Figure 3B ). Golgi-Cox histological analysis revealed dendritic spine reductions in the dentate gyrus of old versus young mice. However, Smpd1 +/À old mice had a dendritic spine density that was similar to that of young mice ( Figure 3C ). Similar results were observed in synaptophysin immunofluorescence analysis ( Figure 3D ).
We also performed an analysis of the Morris water maze (MWM) task and fear conditioning to examine changes of learning and memory. Old mice showed severe deficits in memory formation, whereas Smpd1 +/À old mice were protected from this defect ( Figures 3E and 3F ). Smpd1 +/À old mice also showed reduced anxiety-like behavior compared with old mice (Figures 3G). To analyze the neural activity, we used long-term potentiation (LTP) analysis, but we did not detect differences between old WT and old Smpd1 +/À mice (Figure 3H) . A similar pattern for LTP was observed in a previous study (Gulbins et al., 2013) . Altogether, these results suggested that restored ASM levels in old mice (through genetic inhibition of ASM) delayed neurodegenerative changes and improved behavioral function.
ASM Regulates Endothelial Cell Permeability via Caveolae-Mediated Transcytosis
To investigate more direct insights into the relationship between ASM and endothelial cell permeability, we adopted an in vitro model composed of a monolayer of primary mouse brain endothelial cells cultivated as tight monolayers in chambers for 7-10 days. The cellular confluence and the barrier integrity were confirmed by transendothelial electrical resistance (TEER) values. Cells were treated with 1-10 mM ASM. ASM did not cause endothelial cell death within 6 hr after treatment, though death was observed at 12 and 24 hr ( Figure 4A ). Nevertheless, shortly after ASM treatment, an increased flux of 4 kDa fluorescein isothiocyanate (FITC)-labeled dextran tracers across endothelial cell monolayers was observed without changing the permeability to 70 kDa FITC-labeled dextran ( Figure 4B ). Larger tracers are excluded from the paracellular pathway if intercellular junctions are intact (Coelho-Santos et al., 2016) . In addition, despite the ASM-induced increase in endothelial permeability to small molecular weight tracers, there were no alterations in TEER values ( Figure 4C ), indicating that hyperpermeability promoted by ASM was not due to the disruption of cell monolayers or alterations in the paracellular permeability pathway. Accordingly, no changes were observed in the expression of tight and adherens junction proteins ( Figures 4D and 4E ).
Immunoblotting and electron microscopy (EM) analysis showed that ASM resulted in enhancement of caveolae-mediated transcytosis ( Figures 4F-4H ), but this effect was blocked by ASM antibody treatment ( Figure 4F ). To confirm our observations, we investigated uptake of fluorescence-conjugated BSA and transferrin (Tfn) as indicators of caveolae-and clathrinbased endocytosis, respectively. As expected, ASM-treated cells showed increased BSA uptake, but Tfn uptake did not differ between groups ( Figure 4I ). After ASM treatment, some caveolae colocalized with lysosomes, although most caveolae did not localize in this compartment ( Figure 4J ), implying that ASMmediated caveolae endocytosis was not related to cell death. In addition, expression of efflux transporters was significantly decreased in ASM-treated cells, supporting the in vivo result ( Figures 4K and 4L ). In the absence of ASM, efflux transporters were located in the cell membrane and minimally colocalized with lysosomes, whereas ASM treatment significantly increased colocalization of these with lysosomes ( Figure 4M ). To elucidate the exact mechanisms underlying ASM-induced reduction in these transporters, we examined Rab5 and Rab7 activation, which are early and late endosome markers, respectively, and Lamp1 activation. The results showed that ASM significantly increased Rab5, Rab7, and Lamp1 levels in primary mouse brain endothelial cells ( Figure 4N ). Therefore, these data suggested that ASM induced endocytosis of BBB transporters and its degradation by lysosomes.
To identify caveolae-mediated transcytosis upon ASM exposure, endothelial cells from the brains of Cav-1 À/À mice were used. Depletion of Cav-1 abolished ASM-induced hyperpermeability in endothelial cells without alterations to TEER values (Figures S4A and S4B) , indicating that ASM increases endothelial permeability via caveolae. Expression of junctional proteins was undistinguishable between groups ( Figure S4C ). In addition, efflux of transporters was not reduced in Cav-1 À/À mice-derived cells after ASM treatment ( Figure S4D ). Similar results were observed in endothelial cells from the brains of WT mice treated with methyl-b-cyclodextrin (MbCD, 5 mM), a known caveolae disrupting agent ( Figures S4E and S4F ). Collectively, our results showed that caveolae underlie the transcellular mechanisms responsible for increased endothelial permeability in response to ASM elevation.
The cytoskeleton composed of actin filaments contributes to the structural organization of the cytoplasm in eukaryotic cells. Disassembly of the actin cytoskeleton leads to disruption of endothelial barrier homeostasis and increases vascular permeability (García-Ponce et al., 2015) . Data have revealed complex interactions between the caveolae and the cytoskeleton in maintaining membrane integrity (Stahlhut and van Deurs, 2000) . ASM-treated primary mouse brain endothelial cells showed the loss of filamentous pattern, suggesting that ASM destabilized the filamentous actin network ( Figures 5A and 5B) .
The ERM proteins are cytoskeletal interacting proteins that bind cortical actin and the plasma membrane (Bretscher et al., 2002) and participate in diverse cellular functions (García-Ponce et al., 2015) . A study has shown that ERM proteins could be regulated by sphingolipid (Adada et al., 2014) . ASM treatment evoked a significant dephosphorylation of ERM without change of total ERM levels, and this effect was blocked by ASM antibody ( Figure 5C ). In addition, ASM caused time-and dose-dependent dephosphorylation of ERM ( Figure 5D ). Studies have also revealed that the dephosphorylation of ERM was regulated by protein phosphatase activation, such as protein phosphatase 2A (PP2A) and PP1 (Zeidan et al., 2008) . To further understand the mechanism related to ASM-mediated ERM dephosphorylation, primary mouse brain endothelial cells were incubated with calyculin A (a PP1 and PP2A inhibitor) or okadaic acid (a PP2A inhibitor) for 3 hr before ASM treatment. Pretreatment with calyculin A resulted in a significant block of ASM-induced ERM dephosphorylation. However, okadaic acid did not result in a change of ERM dephosphorylation ( Figures 5E and 5F ), indicating that (B) Representation of brain morphology and quantification of maximal brain diameter in 3-and 20-month-old WT and Smpd1 +/À mice (n = 5 mice per group). (C) Representative high-magnification, bright-field microscopy analysis and quantification of Golgi-Cox staining showing dendritic spine density in the CA1 region of 3-and 20-month-old WT and Smpd1 +/À mice (n = 6 mice per group). Scale bars, 10 mm. (D) Representative immunofluorescence images and quantification of synaptophysin in the brain of 3-and 20-month-old WT and Smpd1 +/À mice (n = 5 mice per group). Scale bars, 50 mm. (E) Morris water maze test in the 3-and 20-month-old WT and Smpd1 +/À mice (n = 10-13 mice per group). (F) Results of contextual and tone tasks during fear conditioning test (n = 7-9 mice per group). (G) Light and dark transition test. Moving distance, time spent, transition number, and first transition time were measured in the 3-and 20-month-old WT and Smpd1 +/À mice (n = 8-12 mice per group). (H) LTP induced by high-frequency stimulation (WT young mice, n = 15 slices from 8 mice; Smpd1 +/À young mice, n = 13 slices from 7 mice; WT old mice, n = 13 slices from 7 mice; Smpd1 +/À old mice, n = 14 slices from 8 mice). (D) mRNA expression and protein levels of junction protein in primary mouse brain endothelial cells after ASM treatment (n = 5-6 independent experiments). (E) Representative image of claudin-5 and VE-cadherin in primary mouse brain endothelial cells after ASM treatment, Scale bar, 20 mm. (F) Left: concentration-dependent effects of ASM on Cav-1 phosphorylation after ASM treatment (n = 3-4 independent experiments). Right: immunoblotting of Cav-1 phosphorylation after ASM treatment with or without ASM antibody (n = 4 independent experiments). (G) EM analysis of primary mouse brain endothelial cells after ASM treatment (n = 8 cells per group). Arrow, luminal vesicles; arrowhead, cytoplasmic vesicles. Scale bar, 500 nm. (H) EM analysis of primary mouse brain endothelial cells after ASM treatment for HRP transcytosis (n = 8 cells per group). Arrowhead, HRP reaction. Scale bar, 500 nm. (I) Primary mouse brain endothelial cells treated by ASM were incubated with A488-BSA (left) or A488-Tfn (right), and then endocytosis was analyzed using a fluorescence microscope (n = 8 independent experiments). Scale bar, 20 mm. (J) Lack of colocalization of caveolae with lysosomes in primary mouse brain endothelial cells exposed to ASM for 10 min. Scale bar, 10 mm. (K and L) mRNA expression (K) and western blot analysis (L) for BBB transporters in primary mouse brain endothelial cells after ASM treatment (n = 5-8 independent experiments). (M) Colocalization of BBB transporters with lysosome in primary mouse brain endothelial cells exposed to ASM for 10 min (n = 6 cells per group). Scale bar, 10 mm. PP1 activation is a key mechanism of ASM-induced ERM dephosphorylation. As expected, cytoskeleton disruption and caveolae-mediated transcytosis were blocked in ASM-treated cells after PP1 inhibition ( Figures 5G-5J) .
It is known that the extracellular signal-regulated kinase 1/2 (Erk1/2) and Akt pathways play an important role in caveolae internalization (Yao and Seger, 2009 ). To find out which upstream signaling pathways of Cav-1 were influenced by ASMmediated ERM dephosphorylation, we examined the changes of Erk1/2 and Akt. Whereas the levels of phospho-Akt were not changed by ASM, phospho-Erk1/2 was markedly increased in ASM-treated cells. This was significantly reduced by PP1 inhibition ( Figure 5K ). This result was confirmed by decreased levels of Cav-1 phosphorylation after Erk1/2 inhibitor treatment in ASM-treated cells ( Figure 5L ).
Finally, old mice vessels showed significantly decreased ERM phosphorylation, which was increased in Smpd1 +/À old mice ( Figure 5M ). Altogether, these data indicated that ASM evoked the disruption of cytoskeleton by PP1-mediated ERM dephosphorylation and that this caused caveolae internalization, leading to endothelial hyperpermeability.
Brain Endothelial Cell-Derived ASM Evokes Aging-like Pathology
To confirm our in vitro observations, we generated conditional transgenic mice with brain endothelial cell-specific overexpression of ASM by crossing loxP-flanked Tg-Smpd stop mice (Gulbins et al., 2013) with Slco1c1-CreERT2 mice (Ridder et al., 2015) (Slco1c1-CreERT2;Smpd1 ox/ox mice). Because ASM is an factor that increases with age, we considered the need for aged Slco1c1-creERT2;Smpd1 ox/ox mice. As seen in Figures  1B-1E , we confirmed that ASM was significantly increased in brain endothelial cells of 20-month-old WT mice compared to 3-month-old WT mice. Based on these results, we anticipated that Slco1c1-creERT2;Smpd1 ox/ox mice might show BBB and neuronal dysfunction at a younger age than 20-month-old WT mice. We confirmed that ASM activity was significantly increased in plasma and brain microvessels of 13-month-old Slco1c1-CreERT2;Smpd1 ox/ox mice compared to age-matched control mice ( Figure 6A ). These data demonstrated that aged Slco1c1-CreERT2;Smpd1 ox/ox mice were suitable to specifically examine the role of brain endothelial-derived ASM in BBB integrity. Compared to age-matched control mice, 13-month-old Slco1c1-CreERT2;Smpd1 ox/ox mice showed reduced vessel density and increased BBB leakage ( Figures 6B-6D ). In addition, we observed increased caveolae-mediated endocytosis and reduced ERM phosphorylation in aged Slco1c1-CreERT2; Smpd1 ox/ox mice (Figures 6E and 6F) . The number of NeuN + cells was significantly decreased in CA1 in aged Slco1c1-CreERT2;Smpd1 ox/ox mice compared to age-matched control mice ( Figure 6G ). To analyze whether disruption of the BBB and reduced neuronal cells affected memory, we performed the MWM test. Aged Slco1c1-CreERT2;Smpd1 ox/ox mice showed severe memory impairments compared to those of age-matched control mice ( Figure 6H ). Altogether, these results suggested that ASM derived from brain endothelium accelerated BBB disruption and evoked aging-like brain pathology.
Endothelial Cell-Specific ASM Knockdown and Pharmacological Inhibition of ASM Improves BBB Integrity and Pathology in Aged Mice
To study ASM-mediated BBB regulation, we performed additional analyses using Smpd1 À/À mice-derived brain endothelial cells. Expression of junctional proteins was undistinguishable between groups ( Figure S5A ). After cellular confluence was ascertained, cultured cells were treated with lipopolysaccharide (LPS), a known ASM-activating factor. Compared to normal mouse endothelial cells, FITC-labeled dextran flux across endothelial cell monolayers was slightly changed in Smpd1 À/À micederived cells after LPS treatment ( Figures S5B and S5C) . A similar result was observed in caveolae-mediated transcytosis by LPS treatment in Smpd1 À/À mice-derived endothelial cells ( Figures S5D and S5E) . After LPS treatment, normal micederived cells exhibited dephosphorylation of ERM, but Smpd1 À/À mice-derived cells showed only a slight change in ERM dephosphorylation ( Figures S5F and S5G) .
To specifically assess the inhibitory effects of ASM in brain endothelial cells on BBB function, we produced endothelial cell-specific GFP-labeled Smpd1 miR RNAi using human Endoglin promoter, which is used to deliver gene specifically to endothelial cells in mice, because it is a small and strong fragment targeting endothelial cells (Velasco et al., 2001) (Figure S6A ). WT old mice received intravenous injection with control miR RNAi or Smpd1 miR RNAi mixed with in vivo-jetPEI for high efficacy of the miR RNAi delivery into the brain endothelial cells Frye et al., 2015; Muramatsu et al., 2012) . Images of brain sections from mice injected with Smpd1 miR RNAi showed successful transfection only into the CD31 + brain endothelial cells in vivo, not into NeuN + , PDGFR-b + , or a-SMA + cells ( Figure S6B ). Flow cytometry analysis with brain microvessels of Smpd1 miR RNAi-treated WT old mice revealed that most CD31 + cells showed a GFP-positive signal but PDGFR-b + and a-SMA + cells did not. NeuN + cells derived from microvesseldepleted brain also did not exhibit a positive signal for GFP ( Figure S6C ). These results strongly indicated high transfection efficiency of Smpd1 miR RNAi in brain endothelial cells in aged mice.
Next, we examined the inhibitory effects of ASM by Smpd1 miR RNAi injection in aged Slco1c1-CreERT2;Smpd1 ox/ox mice and WT old mice. Both 12-month-old Slco1c1-creERT2; Smpd1 ox/ox mice and 17-month-old WT mice were injected in the tail vein with control miR RNAi or Smpd1 miR RNAi mixed with in vivo-jetPEI twice a week for 3 weeks. We first checked Smpd1 mRNA levels in brain microvessels and microvesseldepleted brain by real-time PCR. The results showed selective suppression of Smpd1 mRNA levels in brain microvessels in Smpd1 miR RNAi injected into aged Slco1c1-creERT2; Smpd1 ox/ox mice and WT old mice ( Figure 7A ). Moreover, we confirmed reduction of ASM activity in plasma and brain microvessels in the Smpd1 miR RNAi-injected group ( Figure 7B ). In particular, ASM activity was significantly reduced in CD31 + cells derived from brain microvessels of the Smpd1 miR RNAi-treated group, but not in PDGFR-b + cells and a-SMA + cells ( Figure S6D ). In addition, we observed no difference in ASM activity in other tissues of mice injected with Smpd1 miR RNAi ( Figure S6E ). Therefore, these data indicated successful knockdown of ASM in brain endothelial cells by injection of Smpd1 miR RNAi. Vessel density was increased and microvascular leakage was decreased in the Smpd1 miR RNAi-treated group ( Figures  7C-7F ). Moreover, Smpd1 miR RNAi treatment resulted in reduction of caveolae-mediated transcytosis and ERM dephosphorylation in aged Slco1c1-creERT2;Smpd1 ox/ox mice and WT old mice ( Figures 7G and 7H) . Neuronal density and behavioral function also recovered after Smpd1 miR RNAi treatment in these mice (Figures 7I and 7J) .
We determined whether pharmacological inhibition of ASM with a clinically tested and safe drug (amitriptyline hydrochloride [AMI], an antidepressant) could ameliorate BBB disruption. AMI is a known inhibitor of ASM that can cross the BBB (Gulbins et al., 2013; Lee et al., 2014) . AMI-treated WT old mice exhibited decreased ASM activity and apoptosis of endothelial cells and increased vessel density (Figures S7A-S7D ). In addition, vessel leakages, caveolae-mediated transcytosis, and ERM dephosphorylation were decreased in AMI-treated WT old mice ( Figures  S7E-S7H ). Moreover, neuronal functions recovered after AMI treatment ( Figures S7I and S7J) . These results strongly support our hypothesis that brain endothelial cell-derived ASM has a central role in regulation of aged brain pathology and thus inhibition of endothelial ASM prevents aging by controlling BBB integrity and neuronal function.
DISCUSSION
Until now, changes in sphingolipid metabolic enzymes during aging have been poorly studied. In this study, the brain of aged mice, especially brain endothelium, showed higher ASM activity than other tissues. This implied that brain endothelial ASM might play a significant role in the brain pathology during aging. Although ASM-induced vascular permeability has previously been implicated in the pathogenesis of disorders including diabetic retinopathy (Chakravarthy et al., 2016) , lung edema (Samapati et al., 2012) , and cardiovascular disease (Ohanian et al., 2014) , this study is the first to our knowledge to show the significance of endothelial-derived ASM in BBB breakdown and generation of clinical deficits in aging models.
Brain injury and the consequent destabilization of the BBB have been associated with the upregulation of Cav-1, and its overexpression in the endothelium promotes transcellular trafficking of plasma proteins and contributes to brain edema in BBB disruption models (Knowland et al., 2014; Lutz et al., 2017) . We found that caveolae-mediated transcytosis was increased in aged mice and ASM-treated cells, and reduction of ASM restored endothelial integrity by reducing caveolae internalization. Although previous studies have shown that ASM-mediated caveolae trafficking facilitated repair of plasma membrane in wounded cells and muscle fibers (Corrotte et al., 2013) , our results showed that ASM-induced caveolae internalization increased endothelial cell permeability, resulting in BBB dysfunction. These findings are the first to our knowledge showing that endothelial ASM causes defects of the capillary network and BBB function by interrupting the caveolae system. The importance of major facilitator superfamily domain containing 2a (Mfsd2a) has been reported for the regulation of caveolaemediated transcytosis and BBB permeability (Andreone et al., 2017) . Because increased ASM in aging also affects this BBB dysfunction, we examined expression of Mfsd2a in WT and Smpd1 +/À mice with age. We observed a reduction of Mfsd2a in WT old mice compared to young mice, and this was similar in Smpd1 +/À old mice (data not shown). Although increased ASM in aging does not affect Mfsd2a, we think that further studies are needed to investigate the relationship between mechanism of Mfsd2a reduction and BBB disruption in aging.
Under physiological conditions, actin forms a cortical rim that is associated with cell-cell, cell-matrix adhesion complexes and serves as an anchor of membrane proteins (Stahlhut and van Deurs, 2000) . This anchoring is critical for normal endothelial cell function, and disruption of the actin rim causes cellular remodeling, involving alterations of subcellular structures and hyperpermeability (García-Ponce et al., 2015) . Our results showing that ASM-mediated caveolae internalization is associated with greater cytoskeletal disruption imply that ASM regulates caveolae-cytoskeleton interaction. To investigate this mechanism, we analyzed changes of ERM proteins, which have been previously shown to mediate the actions of ASM in different cellular contexts (Zeidan et al., 2008) . We found that caveolae-cytoskeleton disruption by ASM was related to dephosphorylation of ERM. Our results were supported by several lines of evidence. First, ASM induced ERM dephosphorylation in a time-and concentration-dependent manner. Second, mice specifically overexpressing ASM in brain endothelial cells showed increased ERM dephosphorylation. Finally, downregulation of ASM in mice blocked ERM dephosphorylation of endothelial cells. In this study, we also demonstrated that PP1 is a critical factor for ASM-mediated ERM dephosphorylation. This result is distinct from the previously reported mechanisms of ERM dephosphorylation by PP2A activation (Zeidan et al., 2008) . The differences between the previous study and this study might be related to the cell types that were used. This study focused on the endothelial cells, whereas the previous study used cancer cells.
To our knowledge, Smpd1 loxP/loxP mice for cell-specific deletion of ASM in vivo have not been developed yet. Hence, to analyze the effects of endothelial-specific ASM knockdown in mice, we used Smpd1 miR RNAi with human Endoglin promoter, which has been previously used successfully in mice to deliver genes specifically to endothelial cells (Velasco et al., 2001) . Endoglin is known to be expressed in pericytes and vascular smooth muscle cells, as well as in endothelial cells. However, ASM levels were only high in endothelial cells derived from brain microvessels in old compared to young mice. These were reduced in Smpd1 +/À old mice. In contrast, ASM levels in pericytes or smooth muscle cells of old mice were slightly increased, and ASM levels in these cells were not changed in Smpd1 +/À old mice. Moreover, we observed significant reduction of ASM levels in CD31 + cells derived from brain microvessels of Smpd1 miR RNAi-injected aged Slco1c1-CreERT2;Smpd1 ox/ox mice and WT old mice compared to the control miR RNAi-treated group, but not in PDGFR-b + or a-SMA + cells. Smpd1 miR RNAi-injected aged Slco1c1-CreERT2;Smpd1 ox/ox mice and WT old mice also showed significant protection in both BBB integrity and neuronal function compared to the control miR RNAi-treated group. These data strongly support our hypothesis that ASM derived from brain endothelial cells plays an important role in the regulation of aged-brain pathology, whereby the inhibition of endothelial ASM prevents aging by controlling BBB integrity.
Despite the importance of ASM as a potential drug target for various diseases, including aging (Gulbins et al., 2013; Kornhuber et al., 2015; Zeidan and Hannun, 2010) , potent and selective inhibitors for this enzyme are rare (Arenz, 2010) . The rational development of compounds that block ASM by direct interaction with the enzyme is difficult, because until recently, the crystal structure of the enzyme has not been available. Although some compounds are able to directly inhibit ASM, the specificity and clinical availability of these remain unclear. Some indirect ASM inhibitors have been approved by the Food and Drug Administration, which presented an opportunity to use these drugs in studies aimed at reducing ASM in diseases such as aging. One such drug is AMI, which crosses the BBB and was able to reduce ASM in our aging models. Using this drug, we were able to confirm our hypotheses regarding the role of ASM in BBB integrity during aging. However, a major disadvantage of this and other available inhibitors is the lack of specificity and potential for off-target effects. Crystal structures of mammalian ASM and models describing the organization of the main regions of this enzyme have been described (Gorelik et al., 2016) . Therefore, many researchers, including us, are pursuing the development of highly potent and selective ASM inhibitors that can be used to confirm and extend the studies presented here with AMI.
In summary, the present study reveals a previously unexplored role for endothelium-derived ASM in BBB disruption during aging. Increased ASM levels in endothelium causes endothelial cell death, reduces BBB integrity via caveolae internalization, and results in neuronal dysfunction (Figure 8 ). The molecular mechanisms governing the ASM increase during aging, and the question of whether similar disruption of caveolae-mediated transcytosis by endothelial ASM occurs in humans remains to be explored. Future studies focusing on the relationship between ASM levels in brain endothelium of aging humans and degree of BBB disruption could provide additional information related to these questions.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal models
The following mouse lines were used: C57BL/6 WT mice (The Jackson Laboratory), Smpd1 +/À mice (C57BL/6 background) (Horinouchi et al., 1995) , Smpd1 À/À mice, Cav-1 KO mice (Cav-1 À/À mice, stock number 004585, The Jackson Laboratory), Slco1c1-CreERT2 mice (Ridder et al., 2015) and loxP-flanked Tg-Smpd stop mice (Smpd1 ox/ox mice, C57BL/6 background) (Gulbins et al., 2013) . To obtain brain endothelial cell-specific ASM overexpressing mice, Tg-Smpd stop mice were crossed with Slco1c1-CreERT2 mice.
We used littermate mice that were sex-and age-matched between experimental groups. Both male and female mice were used for all experiments except behavioral studies using male mice. Data analysis was done in 3, 12, and 20-mo-old mice. Cav-1 À/À and Smpd1 À/À mice were used between 6 and 8 weeks of age. Three week-old Smpd1 ox/ox and Slco1c1-CreERT2;Smpd1 ox/ox mice were injected with 1 mg tamoxifen (per 20 g mouse body weight, Sigma-Aldrich, T5648) every 12 hr for five consecutive days and were used 12 or 13 month of age. All animals were randomized for their genotype information and we used block randomization method to allocate the animals to experimental groups. The operators responsible for experimental procedure and data 
Cells
Primary brain endothelial cells of mice (6-8 weeks of age) were cultured as described previously (Ridder et al., 2015) . The brain was homogenized in a Dounce homogenizer, and the resulting homogenate was centrifuged at 2,000 g for 7 min. The pellet was resuspended in 18% dextran solution (mol wt 60,000-90,000; USB, 14495) in DMEM/F12 (Sigma-Aldrich, D6421) and centrifuged at 7,840 g for 10 min. After removing the supernatant and myelin debris, the pellet was resuspended in DMEM/F12 containing 1 mg/mL collagenase/dispase (Roche, 10269638001), 40 mg/mL DNase 1 (Roche, 10104159001), and 0.147 mg/mL tosyllysine chloromethyl ketone (Sigma-Aldrich, T7254) and incubated at 37 C for 75 min with occasional agitation to free endothelial cells from pericytes, perivascular macrophages, and remains of the basement membrane. The cell suspension was centrifuged at 2,000 g for 7 min, the supernatant was discarded, and cells were washed and seeded in 6-well plates coated with mouse collagen IV (BD, 354233). Cells were grown in DMEM/F12 supplemented with 20% fetal bovine serum (GIBCO, 16000036), 2 mM l-glutamine, 100 IU/mL penicillin/100 mg/mL streptomycin/0.25 mg/mL amphotericin B (Sigma-Aldrich, A5955), 100 U/mL heparin (Sigma-Aldrich, H3149), and 30 mg/mL of endothelial cell growth supplement (Sigma-Aldrich, E0760). 4 mg/mL puromycin (Sigma-Aldrich, P8833) was added for the first 48 hr after preparation to deplete cells of nonendothelial origin. Cultures were maintained at 37 C in 5% CO 2 , replaced with fresh medium every 2 days until the cells were reached confluence.
Plasma collection
Mouse blood was collected into ethylenediaminetetraacetic acid (EDTA)-coated tubes via intracardial bleed at time of death. EDTA plasma was generated by centrifugation of freshly collected blood and aliquots were stored at À80 C until use. Human plasma samples were obtained from Kyungpook National University Hospital. Subjects were chosen on the basis of standardized inclusion and exclusion criteria as previously described (Smith et al., 2015) . Participants (n = 48) were males and/or females, declared healthy, and equally divided into younger (n = 24, 24-45 years of age) and older groups (n = 24, 65-90 years of age). Sample size was determined by the G-power software. Informed consent was obtained from all subjects according to the ethics committee guidelines at the Kyungpook National University Hospital.
METHOD DETAILS
Cell culture and treatment The TEER was measured with an EVOM voltohmmeter (WorldPrecision Instruments, Germany) equipped with a STX-2 chopstick electrode at 7-10 days after seeding of primary mouse brain endothelial cells. After confirming the cellular confluence and the barrier integrity, we performed further analysis. Cells were tested to confirm absence of mycoplasma contamination using MycoAlert PLUS Mycoplasma detection kit (Lonza, LT07). Recombinant ASM was kindly provided by Prof. Edward H. Schuchman (Icahn School of Medicine at Mount Sinai, New York, New York, USA) (He et al., 1999) . Cells were treated with recombinant ASM (1-10 mM) or PBS to measure changes of endothelial cell function. Most of the analyses were performed at 10 min after ASM treatment. In some experiments, calyculin A (20 nM, Calbiochem, 208851) and okadaic acid (100 nM, Calbiochem, 459620) were pre-incubated with primary mouse brain endothelial cells for 3 hr to inhibit PP1/PP2A and PP2A, respectively. Erk inhibitor (50 mM, Calbiochem, PD98059) was also pre-incubated with primary mouse brain endothelial cells for 1 hr to suppress Erk1/2 signal. To inhibit the caveolae, Methylb-cyclodextrin (5 mM, Sigma-Aldrich, 332615) was pre-incubated with primary mouse brain endothelial cells for 2 hr. We also used human SMPD1 antibody (3 mg/mL, R&D Systems, MAB5348) or IgG isotype antibody (3 mg/mL, R&D Systems, MAB003) to examine the effects of ASM inhibition.
Cell proliferation and apoptosis assay
At 24 hr after ASM treatment, cell proliferation was measured using EdU (5-ethynyl-2 0 -deoxyuridine) assay kit (Thermo Fisher Scientific, C10339) and cell death was detected by The DeadEnd Fluorometric TUNEL assay kit (Promega, G3250). We examined according to the manufacturer's protocol. The effect of ASM on the growth of primary mouse brain endothelial cells was assessed using the WST-1 assay (Roche, 5015944001). Briefly, seeded cells were treated with ASM (1-10 mM) and incubated for 1 min-24 hr. WST-1 solution was then added to each well, and the cells were further incubated. After 4 hr, the absorbance was measured with a plate reader. These experiments were repeated 4-6 times. Randomization procedures are not applicable to these experiments. Data were collected and analyzed in a double-blind fashion. G-power software was used for sample size estimation. No data were excluded.
Vascular permeability assay
Primary mouse brain endothelial cells were plated on mouse collagen IV -coated 24-well Transwell-Clear inserts with 0.4 mm pore polycarbonate membrane (Costar, Corning, NY, USA). After confirming the cellular confluence and the barrier integrity, growth medium was carefully removed from the insert and replaced with medium containing 10 mM ASM or LPS (0.1 mg/mL, Sigma-Aldrich,
(1:1000, Santa Cruz Biotechnology, sc2005) were used as secondary antibody. We performed densitometric quantification using the ImageJ software and removed irrelevant or blank lanes from blot images in order to present our data in a streamlined way. These experiments were repeated 3-8 times or data were collected from 4-8 mice per group. All data were analyzed in a double-blind fashion. Randomization procedures are not applicable to these experiments. G-power software was used for sample size estimation. No data were excluded.
Transmission electron microscopy (TEM)
In vivo Mice were anesthetized and perfused through the heart with 30 mL PBS, followed by first 150 mL of a 5% glutaraldehyde/4% PFA/0.1 mM phosphate buffer fixative solution, then a 4% PFA/0.1 mM phosphate buffer fixative solution. After perfusion, brains were dissected and fixed by immersion in a 0.1 M sodium-cacodylate-buffered mixture (5% glutaraldehyde and 4% PFA) for 1 hr at room temperature (20 C-25 C) followed by 5 hr in 4% PFA at 4 C. Following fixation, the tissue was washed overnight in 0.1 M sodium-cacodylate buffer and then cut in 50-mm-thick free-floating sections using a vibratome. Sections were then postfixed in 1% osmium tetroxide and dehydrated. After dehydration in ethyl alcohol, the tissue was embedded in epon (Electron Microscopy Sciences). Ultrathin sections of 70 nm were then cut from the block surface, collected on 100 mesh Cu grids (Electron Microscopy Sciences, FCF100-Cu). Grids were contrast stained for 10 min in saturated uranyl acetate, followed by staining in lead citrate for 5 min, and examined under transmission electron microscope (JEM1400-plus). To examine HRP transcytosis, TEM imaging following HRP injection was carried out as described previously (Armulik et al., 2010) . Mice were briefly anesthetized with isoflurane and HRP (10 mg per 20 g mice; Sigma Aldrich, HRP type II) was injected intravenously. After 30 min of circulation, animals were anaesthetized and perfused for clearly observation HRP distribution in vessels. After perfusion, brains were dissected and fixed and then cut in 50-mm-thick free-floating sections using a vibratome. Sections were stained by 3-3 0 diaminobenzidine (DAB) substrate kit (Vector labs, SK-4105) for 10 min at room temperature, and processed for TEM, as described above. To investigate tight junction morphology, mice were anesthetized with isoflurane and HRP was injected intravenously. After 30 min of circulation, brain were dissected and then were processed for TEM. For all TEM quantifications, mean vesicular pit/vesicular density values were calculated from the number of vesicles per mm of membrane for each image collected. Data were collected from 4-6 mice per group (8 capillary cross-sections per mouse) and analyzed in a double-blind fashion. Randomization procedures are not applicable to these experiments. G-power software was used for sample size estimation. No data were excluded. In vitro ASM treated primary mouse brain endothelial cells were fixed in 2.5% glutaraldehyde/4% PFA for 20 min at room temperature. Cells were processed for TEM, as described above. To test HRP transcytosis in vitro, ASM treated primary mouse brain endothelial cells were incubated with HRP (10 mg/mL) for 1 hr. After fixation, cells were incubated with 0.05% DAB and 0.015% hydrogen peroxide in the dark for 5 min at RT, washed with PBS. Cells were then incubated in 2.5% glutaraldehyde/4% PFA for 20 min at room temperature, and processed for TEM. Data were collected from 8 cells per group and analyzed in a double-blind fashion. Randomization procedures are not applicable to these experiments. G-power software was used for sample size estimation. No data were excluded.
Immunogold labeling for electron microscopy
Caveolin-1 immuno-EM labeling was performed as described previously (Andreone et al., 2017) . Mice were anesthetized and perfused through the heart with 30 mL PBS, followed by first 150 mL of a 5% glutaraldehyde/4% PFA/0.1 mM phosphate buffer fixative solution, then a 4% PFA/0.1 mM phosphate buffer fixative solution. Brains were dissected and post-fixed in 4% PFA/PBS for 30 min at 4 C. Coronal vibratome free-floating sections of 50 mm were collected and immersed in 0.1% sodium borohydride/PBS for 20 min at room temperature, blocked with 10% goat serum/PBST (0.01% Triton X-100), and incubated with Caveolin-1 antibody (1:100, Cell Signaling Technologies. 3267) overnight at room temperature. Sections were then incubated with gold-labeled goat antirabbit IgG (1:50, Nanoprobes. 2003) overnight at room temperature, washed with PBS and sodium acetate, and silver-enhanced using Silver Enhancement kit (Sigma, SE100) prior to processing for TEM. Data were collected from 4 mice per group (8 capillary cross-sections per mouse) and analyzed in a double-blind fashion. Randomization procedures are not applicable to these experiments. G-power software was used for sample size estimation. No data were excluded.
In vivo multiphoton microscopy
In vivo multiphoton experiments were performed as previously described (Bell et al., 2010) . After anesthesia, a cranial window was placed over the partial cortex. Blood plasma was labeled by tail vein injection of TMR-dextran (MW = 40 kD; Invitrogen, D1842). In vivo time-lapse images were acquired at 2, 15, and 30 min after TMR-dextran injection. The leakage from cortical vessels (layer II and III, approximately 100 mm from the cortical surface) was captured in each mouse. Quantification was performed by a blinded investigator by measuring the fluorescent signal intensity in 20 randomly selected 20 mm 3 20 mm extravascular areas in brain parenchyma using the NIH ImageJ software integrated density function. Data were collected from 3-6 mice per group and analyzed in a double-blind fashion. Randomization procedures are not applicable to these experiments. G-power software was used for sample size estimation. No data were excluded except when the mice were dead.
